Positive data for Roche multiple sclerosis injection
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Global Phase-3 study initiation expected in the second half of 2024
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Aurigene.AI is an end-to-end solution for small molecule drug discovery
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Subscribe To Our Newsletter & Stay Updated